N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[4-(ethylsulfonyl)phenyl]acetamide | 1426804-74-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[4-(ethylsulfonyl)phenyl]acetamide
• 英文别名: N-[4-bromo-3-(trifluoromethyl)phenyl]-2-(4-ethylsulfonylphenyl)acetamide
• CAS: 1426804-74-1
• 化学式: C₁₇H₁₅BrF₃NO₃S
• 分子量: 450.276
• InChiKey: IYFCNSFWSCJSMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[4-(ethylsulfonyl)phenyl]acetamide 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 、 potassium acetate 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 11.0h， 生成 N-(3'-cyano-4'-(cyclohexylidenemethyl)-2-(trifluoromethyl)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide
  参考文献：
  名称：

  From RORγt Agonist to Two Types of RORγt Inverse Agonists

  摘要：

  Biaryl amides as new ROR gamma t modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with ROR gamma t ligand binding domain (LBD) was resolved, and both "short" and "long" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While "short" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, "long" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.

  DOI：

  10.1021/acsmedchemlett.7b00476
• 作为产物：
  描述：

  2-(4-(乙基磺酰基)苯基)乙酸 、 3-三氟甲基-4-溴苯胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[4-(ethylsulfonyl)phenyl]acetamide
  参考文献：
  名称：

  Discovery of Biaryl Amides as Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors

  摘要：

  A novel series of biaryl amides was identified as ROR gamma t inhibitors through core replacement of a starting hit 1. Structure activity relationship exploration on the biaryl moiety led to discovery of potent ROR gamma t inhibitors with good oral bioavailability and CNS penetration. Compounds 9a and 9g demonstrated excellent in vivo efficacy in EAE mice dose dependently with once daily oral administration.

  DOI：

  10.1021/acsmedchemlett.5b00122

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2013029338A1

  公开（公告）日：2013-03-07

  Disclosed are novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.

  揭示了一种新型的视黄醇相关孤儿受体γ（RORγ）调节剂，以及它们在治疗由RORγ介导的疾病中的用途。